Article

p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas.

Department of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 220, 69120 Heidelberg, Germany.
Neurochemistry International (impact factor: 2.86). 07/2009; 54(7):458-63. DOI:10.1016/j.neuint.2009.01.016 pp.458-63
Source: PubMed

ABSTRACT The p53 tumour suppressor protein has long been recognized as the central factor protecting humans from cancer. In this study we evaluated the associations of p53 status and vessel density (angiogenesis) in a set of diffuse low-grade astrocytomas. Immunohistochemistry was performed on 23 diffuse low-grade astrocytomas for CD31 and p53. Mutations in the TP53 gene were identified by PCR amplification of genomic DNA extracted from the indicated tumour tissues. Microvessel counts were done by computer analyses. Intratumoural or peritumoural microvascular hot spots were assessed and analysed from an image taken with a 200x fold magnification. Statistical analysis was performed with Pearson correlation coefficient and Student's t-test. We found that 9/23 (39%) of the astrocytomas stained positive for p53 in the immunohistochemistry. We identified TP53 mutations in 11/23 (47%) of the astrocytomas. No association between micro vessel density (MVD) and p53 immunohistochemical status was found. However, the MVD was significantly increased in p53 mutated low-grade astrocytomas. Furthermore, the absolute vessel number was significantly higher in p53 mutated than in p53 wild-type low-grade astrocytomas. To analyse the molecular background for that epiphenomenon LN229 glioma cells which harbour a TP53 mutation were transfected with a plasmid encoding p53 wild-type and an angiogenesis protein array was performed. We detected a significant increase for thrombospondin-1, coagulation factor III and serpin E1 and a significant decrease of MMP-9 in wild-type p53 transfected LN229 cells. The higher microvessel density and the increased absolute vessel number in p53 mutated tumours supports the importance of p53 for tumour angiogenesis in diffuse low-grade astrocytomas. Our results support the hypothesis that p53 regulates angiogenesis in low-grade astrocytomas.

0 0
 · 
0 Bookmarks
 · 
54 Views
  • Source
    Article: Mechanisms of resistance to antiangiogenesis therapy.
    [show abstract] [hide abstract]
    ABSTRACT: Angiogenesis, the formation of new blood vessels from existing vasculature, plays an essential role in tumour growth, invasion and metastasis. Vascular endothelial growth factor (VEGF) is one of the key factors responsible for its regulation. High expression of VEGF has been observed in many cancers, and is associated with worse survival. When antiangiogenic agents are used alone they typically initially cause reduction in blood flow or vascular permeability, in many types of cancer. In some cases tumour regression occurs, mainly in renal cancer. In combination with chemotherapy, progression-free survival is often prolonged, but overall survival is not. Many tumours fail to respond initially - de novo resistance. Others develop resistance over time, with progression after a few months of treatment. The mechanisms of resistance are not well understood. The theoretical benefits of VEGF inhibitors are more likely to be realised by understanding these mechanisms and modifying therapy accordingly. This article reviews current knowledge on resistance mechanisms and the therapeutic implications.
    European journal of cancer (Oxford, England: 1990) 03/2010; 46(8):1323-32. · 4.12 Impact Factor

Keywords

angiogenesis protein array
 
coagulation factor III
 
computer analyses
 
diffuse low-grade astrocytomas
 
epiphenomenon LN229 glioma cells
 
higher microvessel density
 
increased absolute vessel number
 
indicated tumour tissues
 
micro vessel density
 
p53 regulates angiogenesis
 
p53 tumour suppressor protein
 
PCR amplification
 
Pearson correlation coefficient
 
peritumoural microvascular hot spots
 
results support
 
significant decrease
 
TP53 gene
 
TP53 mutations
 
tumour angiogenesis
 
wild-type p53 transfected LN229 cells